After 48 weeks of treatment, TPN-101 reduced the levels of neurofilament light chain and interleukin 6, both key biomarkers of neurodegeneration and neuroinflammation in PSP. The Food and Drug ...

HIV-1 reverse transcriptase inhibitors have long been central to antiretroviral therapy, effectively impeding the enzyme responsible for converting viral RNA into DNA – a pivotal step in HIV ...

Viral reverse transcriptase (RT) plays a critical role in replication (e.g., retroviruses, that reverse transcribe RNA templates into complementary DNA) and genome mutations (e.g., ...

Use of nucleoside reverse transcriptase inhibitors (NRTIs), but not other medications for HIV, was associated with a significantly reduced risk for Alzheimer’s disease (AD) in an analysis of two ...

Alzheimer's disease is the most common cause of dementia and affects more than a tenth of Americans aged 65 and older. The disease has proven difficult to develop new treatments for, and available ...